Use of botulinum toxin in depression

Authors

Keywords:

botulinum toxins, depression

Downloads

Download data is not yet available.

Author Biography

Sandra Martínez Pizarro, Hospital comarcal de Huércal Overa

Enfermera

References

1. Parsaik AK, Mascarenhas SS, Hashmi A, Prokop LJ, Vineeth J, Okusaga O, et al. Role of Botulinum Toxin in Depression. J Psychiatr Pract [Internet]. 2016 Mar [citado 21 Ene 2020];22(2):99-110. Disponible en: https://journals.lww.com/practicalpsychiatry/fulltext/2016/03000/Role_of_Botulinum_Toxin_in_Depression.4.aspx

2. França K, Lotti T. Botulinum toxin for the treatment of depression. Dermatol Ther [Internet]. 2017 [citado 21 Ene 2020];30(2):e12422. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/dth.12422

3. Stearns TP, Shad M, Guzman GC. Glabellar Botulinum Toxin Injections in Major Depressive Disorder: A Critical Review. Prim Care Companion CNS Disord [Internet]. 2018 Oct [citado 21 Ene 2020];20(5):18r02298. Disponible en: https://ohsu.pure.elsevier.com/en/publications/glabellar-botulinum-toxin-injections-in-major-depressive-disorder. https://doi.org/10.4088/PCC.18r02298

4. Finzi E, Kels L, Axelowitz J, Shaver B, Eberlein C, Krueger TH, et al. Botulinum toxin therapy of bipolar depression: A case series. J Psychiatr Res [Internet]. 2018 Sep [citado 21 Ene 2020];104:55-57. Disponible en: http://www.botoxfordepression.com/wp-content/uploads/2018/08/BotoxBipolarDepressionJPR.pdf

5. Kruger TH, Wollmer MA. Depression—an emerging indication for botulinum toxin treatment. Toxicon [Internet]. 2015 Dec [citado 21 Ene 2020];107(Pt A):154-7. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0041010115300945

6. Chugh S, Chhabria A, Jung S, Kruger THC, Wollmer MA. Botulinum Toxin as a Treatment for Depression in a Real-world Setting. J Psychiatr Pract [Internet]. 2018 Jan [citado 21 Ene 2020];24(1):15-20. Disponible en: https://journals.lww.com/practicalpsychiatry/Fulltext/2018/01000/Botulinum_Toxin_as_a_Treatment_for_Depression_in_a.3.aspx

7. Magid M, Keeling BH, Reichenberg JS. Neurotoxins: expanding uses of neuromodulators in medicine—major depressive disorder. Plast Reconstr Surg [Internet]. 2015 Nov [citado 21 Ene 2020];136(5 Suppl):111S-119S. Disponible en: https://journals.lww.com/plasreconsurg/Abstract/2015/11001/Neurotoxins__Expanding_Uses_of_Neuromodulators_in.20.aspx

8. Zamanian A, Ghanbari Jolfaei A, Mehran G, Azizian Z. Efficacy of botox versus placebo for treatment of patients with major depression. Iran J Public Health [Internet]. 2017 Jul [citado 21 Ene 2020];46(7):982-984. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563881/

9. Brin MF, Durgam S, Lum A, James L, Liu J, Thase ME, et al. Onabotulinum toxin A for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int Clin Psychopharmacol [Internet]. 2020 Jan [citado 21 Ene 2020];35(1):19-28. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903360/

Downloads

Published

2020-07-06

How to Cite

1.
Martínez Pizarro S. Use of botulinum toxin in depression. Acta Méd Centro [Internet]. 2020 Jul. 6 [cited 2025 Jul. 1];14(3):394-7. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/1258

Issue

Vol. 14 No. 3 (2020): July-September

Section

Letters to the Editor

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).